Enanta Pharmaceuticals (ENTA) Total Non-Current Liabilities (2012 - 2026)

Enanta Pharmaceuticals has reported Total Non-Current Liabilities for 15 years, with the latest figure at $197.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 13.69% year-over-year to $197.8 million; the trailing twelve-month figure through Mar 2026 stood at $197.8 million (down 13.69% YoY), and the FY2025 full-year result was $215.8 million, down 12.86% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $197.8 million, down from $202.6 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $256.9 million in Q2 2023, with the low at $46.3 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $178.6 million across 5 years, with a median of $221.5 million in 2025.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities slipped 17.17% — and 2023, when it jumped 448.55%.
• Enanta Pharmaceuticals' Total Non-Current Liabilities stood at $46.3 million in 2022, then jumped by 409.83% to $236.0 million in 2023, then increased by 0.26% to $236.6 million in 2024, then decreased by 14.35% to $202.6 million in 2025, then retreated by 2.37% to $197.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $197.8 million (Q1 2026), $202.6 million (Q4 2025), and $215.8 million (Q3 2025), per Business Quant data.